Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Regulation of PD-L1 expression in the tumor microenvironment
M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
F Li, C Li, X Cai, Z Xie, L Zhou, B Cheng, R Zhong… - …, 2021 - thelancet.com
Background The responses of cancer patients to immune checkpoint inhibitors (ICIs) vary in
success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This …
success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This …
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
S Qin, L Xu, M Yi, S Yu, K Wu, S Luo - Molecular cancer, 2019 - Springer
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
Ovarian cancer immunotherapy and personalized medicine
S Morand, M Devanaboyina, H Staats… - International Journal of …, 2021 - mdpi.com
Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …
sensitive/resistant target treatment subpopulations based on stratification by tumor …
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
P Zhao, L Li, X Jiang, Q Li - Journal of hematology & oncology, 2019 - Springer
Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …
persistently popular topic in cancer research because they tremendously improve the …
[HTML][HTML] Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Background Agents blocking programmed cell death protein 1/programmed death-ligand 1
(PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the …
(PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the …
[HTML][HTML] Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance
J Yan, D Liu, J Wang, W You, W Yang, S Yan… - Drug Resistance …, 2024 - Elsevier
Abstract Chaperone-mediated autophagy (CMA), a proteolytic system contributing to the
degradation of intracellular proteins in lysosomes, is upregulated in tumors for pro …
degradation of intracellular proteins in lysosomes, is upregulated in tumors for pro …
A decade of FDA-approved drugs (2010–2019): trends and future directions
A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
M Yi, D Jiao, S Qin, Q Chu, K Wu, A Li - Molecular cancer, 2019 - Springer
Immune checkpoint inhibitor (ICI) activates host's anti-tumor immune response by blocking
negative regulatory immune signals. A series of clinical trials showed that ICI could …
negative regulatory immune signals. A series of clinical trials showed that ICI could …